(PJP) Invesco Dynamic - Ratings and Ratios
Pharmaceutical Stocks, Research, Development, Manufacturing, Distribution
Description: PJP Invesco Dynamic October 29, 2025
The Invesco Dynamic Pharmaceuticals ETF (NYSE ARCA:PJP) seeks to track an index of 30 U.S. pharmaceutical companies, allocating at least 90 % of its assets to the underlying securities. Because the index is limited to a relatively small number of stocks, the fund is classified as non-diversified, which can amplify both sector-specific upside and downside risk.
Key quantitative points (as of Q3 2024) include an expense ratio of 0.55 % and a weighted-average market-capitalization of roughly $45 billion, indicating a tilt toward large-cap innovators. The top holdings are typically leaders such as Pfizer, Merck & Co., and Eli Lilly, whose combined R&D intensity averages about 15 % of revenue-well above the S&P 500 average of 4 %. Recent sector drivers include an aging U.S. population (projected to reach 21 % of the total by 2030) and a modest rebound in drug-price growth after the 2022-23 pricing reform cycle, both of which support earnings expansion for companies with strong pipeline assets.
If you want a deeper, data-rich view of how PJP’s exposure aligns with emerging pharmaceutical trends, a quick look at ValueRay’s analytics can help you surface the most relevant risk-adjusted performance metrics.
PJP ETF Overview
| Market Cap in USD | 269m |
| Category | Health |
| TER | 0.57% |
| IPO / Inception | 2005-06-23 |
PJP ETF Ratings
| Growth Rating | 50.3% |
| Fundamental | - |
| Dividend Rating | 55.0% |
| Return 12m vs S&P 500 | -6.36% |
| Analyst Rating | - |
PJP Dividends
| Dividend Yield 12m | 1.03% |
| Yield on Cost 5y | 1.67% |
| Annual Growth 5y | 10.43% |
| Payout Consistency | 85.1% |
| Payout Ratio | % |
PJP Growth Ratios
| Growth Correlation 3m | 89.6% |
| Growth Correlation 12m | 30.2% |
| Growth Correlation 5y | 61.3% |
| CAGR 5y | 9.43% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.58 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.03 |
| Sharpe Ratio 12m | 1.15 |
| Alpha | -1.09 |
| Beta | 0.640 |
| Volatility | 12.99% |
| Current Volume | 7.1k |
| Average Volume 20d | 5k |
| Stop Loss | 94 (-3%) |
| Signal | 1.66 |
What is the price of PJP shares?
Over the past week, the price has changed by +0.53%, over one month by +4.84%, over three months by +16.27% and over the past year by +11.10%.
Is Invesco Dynamic a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PJP is around 92.61 USD . This means that PJP is currently overvalued and has a potential downside of -4.45%.
Is PJP a buy, sell or hold?
What are the forecasts/targets for the PJP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 103.1 | 6.4% |
PJP Fundamental Data Overview October 20, 2025
Beta = 0.64
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 269.1m USD (269.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 269.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 269.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.37% (E(269.1m)/V(269.1m) * Re(8.37%) + (debt-free company))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for PJP ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle